Sep 18, 2022

Bluebird’s Gene Therapy for Brain Disease Receives Accelerated Approval

Posted by in categories: biotech/medical, neuroscience

Bluebird Bio Inc.’s gene therapy for a brain-wasting disease received accelerated approval from U.S. regulators, making it the first treatment of its kind for children living with cerebral adrenoleukodystrophy.

Leave a reply